Thermo Fisher Scientific Opens Doe & Ingalls Northeast cGMP Chemical Distribution Facility
Thermo Fisher Scientific Inc. has announced the opening of its new Doe & Ingalls Northeast cGMP chemical distribution facility to meet the growing demand for quality compliance, production chemical storage and supply chain services for the biopharmaceutical, life science and advanced technology markets.
“A secure, robust supply chain is crucial for manufacturers to remain competitive, reduce total cost of ownership and mitigate risk of supply interruption,” said Jeff Jochims, president, research and safety markets, Thermo Fisher Scientific. “Our new Doe & Ingalls facility offers customers the ability to ramp up or expand their production capabilities quickly and cost-efficiently. By leveraging our scale and depth of capabilities in production materials supply chain, our customers can focus their internal resources on what they do best — developing new pharmaceuticals and technologies.”
Located in Peabody, Mass., the 56,000 sq ft, state-of-the-art facility is designed to protect raw material integrity, control the flow of goods and deliver supply chain services. The facility is cGMP-compliant to assure products and processes are in strict compliance with regulatory agencies and meet and/or exceed standards for temperature control, audit log/documentation and product handling/sampling. Innovative supply chain services include
• Storage and warehousing of chemical and raw materials
• Dip tube exchange and temperature-controlled 2-8°C cold storage
• ISO Class 8 and Class 100 cleanrooms provide sampling services for sourcing and quality control (QC) testing of production chemical materials.
“We welcome and celebrate this expansion,” said Massachusetts Governor Deval Patrick. “This facility underscores Thermo Fisher’s commitment to the leading life sciences supercluster in the world.”
“We congratulate Thermo Fisher on the opening of the Doe & Ingalls site,” said Robert K. Coughlin, president and chief executive officer of MassBio, a life sciences trade organization. “This site will be an excellent resource for our members, many of whom are challenged to operate as a GMP-compliant operation when it’s time to scale up to pilot manufacturing. This facility will provide critical services to get them up and running, shortening the time it takes to get new products to market and to the patients who need them.”
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...